Plus therapeutics reports first quarter 2024 financial results and recent business highlights

Announced private placement of up to $19.25m with healthcare funds and insiders received $3m award recommendation from the department of defense to support plus' clinical brain cancer program acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive top-line foresee clinical trial data management to host conference call may 15, 2024 at 5:00 p.m. et austin, texas, may 15, 2024 (globe newswire) -- plus therapeutics, inc.  (nasdaq:  pstv ) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended march 31, 2024, and provided an overview of recent and upcoming business highlights.
pstv Ratings Summary
pstv Quant Ranking